WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. - Wikidata - awgldk - TriplyDB

WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.

WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.

http://www.wikidata.org/entity/Q39427761

about

Splicing Regulation: A Molecular Device to Enhance Cancer Cell Adaptation Splicing Regulators and Their Roles in Cancer Biology and Therapy Connecting the speckles: Splicing kinases and their role in tumorigenesis and treatment response Phosphorylation-mediated regulation of alternative splicing in cancer Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340)Expression analysis of an evolutionarily conserved alternative splicing factor, Sfrs10, in age-related macular degeneration Rolling-circle transposons catalyze genomic innovation in a mammalian lineage Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt.ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone.Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina.Metformin decreases progerin expression and alleviates pathological defects of Hutchinson-Gilford progeria syndrome cells.Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma Elevated SRPK1 lessens apoptosis in breast cancer cells through RBM4-regulated splicing events.Specific inhibition of serine/arginine-rich protein kinase attenuates choroidal neovascularization.The RNAissance family: SR proteins as multifaceted regulators of gene expression Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.Detection of VEGF-A(xxx)b isoforms in human tissues Epidermal growth-factor-induced transcript isoform variation drives mammary cell migration.Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant.Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing Alternative RNA splicing and cancer Serine-arginine protein kinase 1 promotes a cancer stem cell-like phenotype through activation of Wnt/β-catenin signalling in NSCLC.The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus.A summary of relationships between alternative splicing and breast cancer.VEGFA splicing: divergent isoforms regulate spermatogonial stem cell maintenance.The role of VEGF 165b in pathophysiology Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion.Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level.Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy.SRPK1 Dissimilarly Impacts on the Growth, Metastasis, Chemosensitivity and Angiogenesis of Glioma in Normoxic and Hypoxic Conditions.RNA splicing factors as oncoproteins and tumour suppressors.Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells.Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel.SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.Regulation of splicing by SR proteins and SR protein-specific kinases.

P2860

Q26798148-A4E24475-074A-4F90-AC40-5A6A32FE84DA Q26798158-BEE6A8A9-09DF-49F6-B44C-A196D4B54967 Q26824298-206A02B5-A528-47DF-9FBF-3F3349F9DE4D Q27009883-BBCE44BD-9796-47B7-A5CC-A6345C454CE3 Q27342809-7A1FF0E3-377F-494C-BD5A-A007544ABCC4 Q28251240-FCC1660D-18BE-42BB-87C9-E82D0F89F195 Q28547020-538D9D69-928A-4160-9041-F5AEA2D6F3AC Q28582788-61C85319-E879-47AB-BEE5-4630B29EC09B Q28652547-718C6BD7-6AD2-483C-98AF-F28A41ACB8B3 Q33605329-BCDB95B1-F38B-4F87-83B2-69A97381FDC0 Q33739392-B49AA9A9-6D63-403C-B837-7E7F136B4DAE Q33742338-5794501C-DCD0-4A51-9DD0-6661A021CC99 Q33914338-2AC72D8E-B3DD-4589-B8AA-8A9C3EC86CD7 Q33994399-0A4B885E-D2DD-48D5-8F0D-B19BA14C3912 Q34240895-75A27944-21CE-47B6-8932-CBA448A5C31E Q34656053-752353B6-E45A-459B-BF18-6CA5C12FB8E2 Q34717851-BB0B42D4-3EB7-43CE-8079-2FABBD0554DB Q34854858-79938523-C596-4FCD-8D0B-CD036D059179 Q34918179-58F669D3-9844-4322-A1BF-B7DC37A74265 Q35063756-2971850F-5817-46DA-B3C2-F1CD28141064 Q35408783-386044B2-255E-4BD5-ADED-47B35D568F1F Q35541632-6FBE0BE1-8B6C-4D4D-9FC6-AA553D6570D1 Q35589667-AD36CDDC-43B8-417E-B258-A33F1D0E4DED Q36071281-9727565A-F571-4685-8CB2-6B6D17734EC6 Q36161960-B4E70592-CAAE-4472-ACFD-AC95F9C202A9 Q36378283-8B3E9911-24CF-4A6E-83C0-2D2C35A92024 Q36436720-97F4D896-7FB4-4110-BA17-A378EF1B4E0C Q36542093-D05F0244-2969-4314-A07B-CA644EEE13D5 Q36577277-ED47DE48-F8FC-4BDC-8D02-3A615C0B276B Q36771977-89145A0E-D5BA-4566-B4ED-8731ACFF81C8 Q37166978-9D814335-0E1A-4646-8A1E-11C48AAEBD6B Q37197773-7F97B0F3-CF69-4232-BA4D-159B2594B787 Q37304724-063A9C3A-40E6-4D50-B73B-D9BCA970E823 Q37347529-C8ED4FBA-D95D-474F-AA90-7ADEA98F2EE0 Q37391660-36138228-1847-4845-80EB-7FCB91652491 Q37661658-AB4972E4-434A-4D01-9049-952D8859604B Q37705932-8089F9FC-1D68-42C2-A5F9-9CBF4CEE1560 Q37721627-7FB27302-42AA-4FF3-920A-A881DA8EA96B Q38027969-32137147-2701-46C7-B307-126819BB450D Q38092678-BDBB2117-0784-4B68-8F50-03DE4CAB087D

P2860

WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.

http://www.wikidata.org/entity/Q39427761

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

WT1 mutants reveal SRPK1 to be ...... get by altering VEGF splicing.

@en

WT1 mutants reveal SRPK1 to be ...... get by altering VEGF splicing.

@nl

type

label

WT1 mutants reveal SRPK1 to be ...... get by altering VEGF splicing.

@en

WT1 mutants reveal SRPK1 to be ...... get by altering VEGF splicing.

@nl

prefLabel

WT1 mutants reveal SRPK1 to be ...... get by altering VEGF splicing.

@en

WT1 mutants reveal SRPK1 to be ...... get by altering VEGF splicing.

@nl

P1433

Q39427761-3785576E-B7D2-499E-89FF-48E5EA420F56

P1476

Q39427761-EB533038-2A62-4FE3-8737-FCE0A39ED822

P2093

Q39427761-02FAE1A6-9744-402F-B1B6-5BBF0EFC0D3B

Q39427761-05BE3F4E-877F-44DD-89FC-3FD53B84ADC1

Q39427761-07C02DF7-751C-48BB-82BA-CDCEFC77F2EA

Q39427761-0B1B4BE6-9453-443E-AFDC-9EF719BC9028

Q39427761-2819DA62-37EF-4496-8609-FFAAA594A1BC

Q39427761-42E7E429-1541-48B2-B621-1C38A42D4DCE

Q39427761-44E66ABA-3848-443C-AAB0-FD25821A0E39

Q39427761-52749244-4264-4345-9919-DFCDFB2BB919

Q39427761-714FDB4E-606E-4481-8110-8027385F1203

Q39427761-73413415-58DC-48B8-A528-D5BD74F8B423

P2860

Q39427761-05CC7E2B-F3EC-4D00-ABA6-3868786A500A

Q39427761-066A21A5-8720-4EAA-80E6-59481A541BEA

Q39427761-2B781659-9121-4843-89F9-202422B31BB1

Q39427761-2EF47862-25AD-4D20-A696-A68C62DFB8CF

Q39427761-3FC9253D-A567-4793-988E-810B665F6E8A

Q39427761-44491109-F1F9-4507-9990-490BB2550358

Q39427761-4CF8C691-3841-44BA-97A6-5DBC920D244F

Q39427761-534682AB-C097-4CB8-898F-FEF35BC7CD39

Q39427761-5C17999B-57CB-4666-A481-D8CB356F232B

Q39427761-5E20FBB9-4714-4533-B7F5-7E390DB89DFE

P304

Q39427761-DD6B09B5-B728-46A7-B0B6-BAD5594D8B58

P31

Q39427761-7D89B5F0-BFAE-4478-894E-2A820CC2E4B1

P356

Q39427761-BF9389CF-A13C-4DF7-910D-5F504BA24D8A

P433

Q39427761-CB3292B8-F41E-42AC-AB58-31FDDF775A8D

P478

Q39427761-8577A5C8-5840-4D21-8B15-8BE5D7385BFD

P50

Q39427761-59624C73-2527-46AB-85D6-7A4667F36CC1

Q39427761-D08BABEC-4368-4570-8A65-79DF7193DD99

P577

Q39427761-6971A47C-4A69-4686-A998-02713C2E7F5E

P5875

Q39427761-9E995F1A-41F8-4E6E-B5FD-6B43946967BC

P698

Q39427761-15C08047-831E-4C4A-9703-AA2095C26777

P932

Q39427761-87B0ED85-5B56-4E5D-9F92-A8DE1CDD2060

P356

J.CCR.2011.10.016

P1433

P1476

WT1 mutants reveal SRPK1 to be ...... get by altering VEGF splicing.

@en

P2093

David O Bates

http://www.w3.org/2001/XMLSchema#string

David R Hinton

http://www.w3.org/2001/XMLSchema#string

Dawid G Nowak

http://www.w3.org/2001/XMLSchema#string

Elianna M Amin

http://www.w3.org/2001/XMLSchema#string

Emma S Rennel

http://www.w3.org/2001/XMLSchema#string

Gavin I Welsh

http://www.w3.org/2001/XMLSchema#string

Jing Hua

http://www.w3.org/2001/XMLSchema#string

Kirsty E Symonds

http://www.w3.org/2001/XMLSchema#string

Lan Ni

http://www.w3.org/2001/XMLSchema#string

Man-Kim Cheung

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of human p53 activity and cell localization by alternative splicing

WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Association of an anatomo-pathological syndrome of male pseudohermaphroditism, Wilms' tumor, parenchymatous nephropathy and XX/XY mosaicism

A syndrome of pseudohermaphroditism, Wilms' tumor, hypertension, and degenerative renal disease

The many facets of the Wilms' tumour gene, WT1

Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis

The Wilms' tumor 1 (WT1) gene (+KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron.

Overexpression of VEGF165b in podocytes reduces glomerular permeability.

The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

P304

768-780

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2011.10.016

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Brigitte Royer-Pokora

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51882725

http://www.w3.org/2001/XMLSchema#string

P698

22172722

http://www.w3.org/2001/XMLSchema#string

P932

3574979

http://www.w3.org/2001/XMLSchema#string